Pharmafile Logo

News and Press Releases

AES Cleanroom Technology Marks 40 Years of Innovation at INTERPHEX 2026

21 April 2026 -- Pennsylvania, US -- AES Cleanroom Technology, a leading provider of modular cleanroom design, manufacturing, and construction solutions for the life sciences and biopharmaceutical industries, is celebrating...

Category: Biotechnology, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: April 21, 2026

AES Clean Technology
422 Stump Road, Montgomeryville, PA 18936

Samsung Bioepis Presents Nonclinical Data for its First Novel Antibody-Drug Conjugate Candidate SBE303 at AACR 2026  

Nonclinical findings from pharmacology, pharmacokinetics, and toxicology studies support the advancement of SBE303 into clinical development with a favorable therapeutic index (TI), with its first-in-human Phase I clinical trial began...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 20, 2026

Samsung Bioepis
76, Songdogyoyuk-ro, Yeonsu-gu, Incheon

Integrated DNA Technologies Expands Coralville Manufacturing Footprint to Support Growing Global Demand for MRD Solutions

Expanded footprint delivers speed, scale and customization minimal residual disease (MRD) innovators need without compromising quality Increased production capacity leverages IDT’s highly specialized, high-throughput manufacturing platform. 20 April 2026 --...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: April 20, 2026

Integrated DNA Technologies (IDT)
custcare@idtdna.com

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026 

Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies and key biomarkers identified AT-108 combines the advantages of an off-the-shelf gene therapy whilst offering a...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2026

Asgard Therapeutics
info@asgardthx.com
Medicon Village, 223 81 Lund, Sweden

STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications First‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation 16 April...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 16, 2026

Storm Therapeutics
info@stormtherapeutics.com
Babraham Hall House, Babraham, Cambridge CB22 3AT

Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

First patient dosed in France, expanding the DOMISOL study beyond Australia DT 7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program. 9...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 9, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

Novonesis expands global footprint with acquisition of production facility in Southeast Asia

Investment of around USD 50 million strengthens fermentation capabilities and supports the company’s long-term growth ambitions 8 April 2026 -- Copenhagen, Denmark -- Novonesis has signed an agreement with Meihua to...

Category: Manufacturing and Packing, Other, Pharmaceutical
Posted: April 8, 2026

Novonesis
Biologiens Vej 2 2800 Lyngby Denmark

ESCMID Global 2026: Shionogi presents new real-world data highlighting clinical effectiveness of Fetroja/Fetcroja (cefiderocol) in MBL-producing Enterobacterales infections

Real world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 83% overall survival at day 28, for patients infected with highly resistant metallo-beta...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 7, 2026

SHIONOGI
contact@shionogi.eu
33 Kingsway, London, WC2B 6UF, UK

Symeres and Ambagon Therapeutics collaborate on molecular glue research in colorectal cancer

31 March 2026 -- Nijmegen, Netherlands -- Symeres, a leading CRDMO for drug discovery and development has partnered with Ambagon Therapeutics, a pre-clinical biotechnology company, to explore a new class...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 31, 2026

Johnson & Johnson’s DARZALEX (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma Milestone is a testament to ten years of daratumumab experience and innovation, continuing...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: March 27, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance. 10 March...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

Neuland to open commercial peptide facility as part of planned phased expansion

The CDMO’s Module 1 commercial production facility to be operational by summer 2026 9 March 2026 -- Hyderabad, India -- Neuland Laboratories  will open its new commercial peptide facility in the...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: March 9, 2026

Neuland Labs
11th Floor (5th Level), Phoenix IVY Building, Plot No. 573A-III, Road No. 82, Jubilee Hills, Hyderabad, 500033, Telangana, India.

Medidata Expands Partnership with The Menarini Group, Deploying Medidata’s Study Build AI Technology to Accelerate Global Oncology Pipeline

Fourteen-year collaboration enters a new phase as Menarini evolves its use of the Medidata Platform, combining established clinical workflows with AI to power its global oncology pipeline 9 March 2026...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026

Medidata
helpdesk@mdsol.com
350 Hudson Street New York, NY 10014 USA

European Commission approves AKEEGA (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC)

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall survival versus standard...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles 26 February 2026 -- Massachusetts, US...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 3, 2026

Curium Pharma
contactus@curiumpharma.com
Perceptive 55 Blue Sky Drive Burlington Massachusetts 01803 United States